Disruptive innovation in online marketing for pharmaceuticals
M3 is a leader in online marketing for medical products. Over the years, M3 has built a huge following among doctors, with it’s platform dominating this niche market segment with more than 5mn doctor subscribers globally.
More importantly, it has also monetised this relationship and as a result, generated high cash flow with a conversion ratio of 97% (net income/ free cash flow).
Pharmaceutical companies have been taking note and are increasingly turning to more efficient marketing methods to preserve margins. By using ‘pay-for-performance’ services to promote their products directly to doctors on M3’s medical platform, the costs of hiring traditional medical representatives could be reduced significantly.
We first initiated a position in the company in 2017. M3 is a leader in a niche market with an economic moat and we believe their entrepreneurial culture and innovative mind-set should see continued growth as it invests into new business areas and overseas acquisitions. We believe M3 is on the right side of disruption and could become a much larger company in the next 5-10 years.
Source: SMBC, company data, as at March 2019.
Disclaimer: Reference to specific securities (if any) is included for the purpose of illustration only and should not be construed as a recommendation to buy or sell the same. All securities mentioned herein may or may not form part of the holdings of FSSA Investment Managers' portfolios at a certain point in time, and the holdings may change over time.